Cargando…

Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma

SIMPLE SUMMARY: Checkpoint inhibitors have emerged as an effective therapy for patients with metastatic melanoma significantly improving survival for these patients. Despite this, many patients do not respond to the therapy and no current biomarkers can identify responders from non-responders. Using...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pedersen, Jesper Geert, Sokac, Mateo, Sørensen, Boe Sandahl, Luczak, Adam Andrzej, Aggerholm-Pedersen, Ninna, Birkbak, Nicolai Juul, Øllegaard, Trine Heide, Jakobsen, Martin Roelsgaard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322974/ https://www.ncbi.nlm.nih.gov/pubmed/35884403 http://dx.doi.org/10.3390/cancers14143342

Ejemplares similares

Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors
por: Pedersen, Jesper Geert, et al.
Publicado: (2020)

Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel
por: Kisistók, Judit, et al.
Publicado: (2023)

Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2016)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

cGAS-STING pathway expression as a prognostic tool in NSCLC
por: Raaby Gammelgaard, Kristine, et al.
Publicado: (2021)

Rhabdomyosarcoma in Adults: A Retrospective Analysis of Case Records Diagnosed between 1979 and 2018 in Western Denmark
por: Mäkinen, Vivi-Nelli, et al.
Publicado: (2021)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018)

Ipilimumab/nivolumab: Diffuse pneumonitis: case report
Publicado: (2020)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
por: Towner, Mary, et al.
Publicado: (2022)

The ratio of adaptive to innate immune cells differs between genders and associates with improved prognosis and response to immunotherapy
por: Ahrenfeldt, Johanne, et al.
Publicado: (2023)

Computational Analysis Reveals the Temporal Acquisition of Pathway Alterations during the Evolution of Cancer
por: Ahrenfeldt, Johanne, et al.
Publicado: (2022)

Classifying cGAS-STING Activity Links Chromosomal Instability with Immunotherapy Response in Metastatic Bladder Cancer
por: Sokač, Mateo, et al.
Publicado: (2022)

Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience()
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2019)

Inflammation scores as prognostic biomarkers in small cell lung cancer: a systematic review and meta-analysis
por: Winther-Larsen, Anne, et al.
Publicado: (2021)

Hyponatremia as a prognostic factor in non-small cell lung cancer: a systematic review and meta-analysis
por: Sandfeld-Paulsen, Birgitte, et al.
Publicado: (2021)

Inflammation-scores as prognostic markers of overall survival in lung cancer: a register-based study of 6,210 Danish lung cancer patients
por: Winther-Larsen, Anne, et al.
Publicado: (2022)

Pretreatment Albumin-to-Alkaline Phosphatase Ratio Is a Prognostic Marker in Lung Cancer Patients: A Registry-Based Study of 7077 Lung Cancer Patients
por: Sandfeld-Paulsen, Birgitte, et al.
Publicado: (2021)

Spatial transformation of multi-omics data unlocks novel insights into cancer biology
por: Sokač, Mateo, et al.
Publicado: (2023)

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
por: Marchetti, Paolo, et al.
Publicado: (2020)

Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
por: Brastianos, Priscilla K., et al.
Publicado: (2021)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
por: Shitara, Kohei, et al.
Publicado: (2022)

Ipilimumab/nivolumab/tozinameran: Various toxicities: case report
Publicado: (2022)

Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
por: Reichert, Constance, et al.
Publicado: (2023)

A Validated Prognostic Biomarker Score for Adult Patients with Nonmetastatic Soft Tissue Sarcomas of the Trunk and Extremities
por: Maretty-Kongstad, Katja, et al.
Publicado: (2017)

The Importance of Reference Gene Analysis of Formalin-Fixed, Paraffin-Embedded Samples from Sarcoma Patients — An Often Underestimated Problem()()
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2014)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
por: Suozzi, Kathleen C., et al.
Publicado: (2016)

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
por: Tan, Irena, et al.
Publicado: (2018)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Ipilimumab/nivolumab: Immune-related pneumonitis: 2 case reports
Publicado: (2020)

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies
por: Zhang, Jason, et al.
Publicado: (2019)

Ipilimumab/nivolumab/tozinameran: Severe necrotizing myopathy: case report
Publicado: (2022)

Cabozantinib/ipilimumab/nivolumab interaction: Haemophagocytic lymphohistiocytosis: case report
Publicado: (2021)

Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms
por: Al-Toubah, T., et al.
Publicado: (2021)

Ipilimumab/nivolumab/tozinameran: Acute myocarditis: 3 case reports
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o7csjihk8sq3jbb9i5vsq7fj06